Trial comparisons

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=85

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT04536038-sae",
        "title": "Opt-in vs Opt-out: serious adverse events",
        "summary": "1 of 3909 against 4 of 1267; risk difference -0.3 points, 95% interval -0.8 to -0.1; NCT04536038, Framing Clinical Trial Enrollment for Patients With Peripheral Artery Disease",
        "record": "/library/comparisons/NCT04536038-sae",
        "nct_id": "NCT04536038",
        "kind": "serious-adverse-events",
        "participants": 5176,
        "risk_difference": {
          "value": -0.0029012440277561566,
          "lower": -0.00783810181228487,
          "upper": -0.0006339847844966133
        },
        "group_1": "1 of 3,909",
        "group_2": "4 of 1,267",
        "difference": "-0.3 points",
        "interval": "-0.8 to -0.1",
        "trial_title": "Framing Clinical Trial Enrollment for Patients With Peripheral Artery Disease"
      },
      {
        "id": "NCT04625725-1e59c014",
        "title": "AZD7442 vs Placebo: The Incidence of SARS-CoV-2 RT-PCR-positive Severe or Critical Symptomatic Illness Occurring After Dosing With IMP",
        "summary": "2 of 3441 against 11 of 1731; risk difference -0.6 points, 95% interval -1.1 to -0.3; NCT04625725, Phase III Double-blind, Placebo-controlled Study of AZD7442 for Pre-exposure Prophylaxis of COVID-19 in Adult.",
        "record": "/library/comparisons/NCT04625725-1e59c014",
        "nct_id": "NCT04625725",
        "kind": "outcome",
        "participants": 5172,
        "risk_difference": {
          "value": -0.005773481873442739,
          "lower": -0.010780081266573573,
          "upper": -0.0025776978183783086
        },
        "group_1": "2 of 3,441",
        "group_2": "11 of 1,731",
        "difference": "-0.6 points",
        "interval": "-1.1 to -0.3",
        "trial_title": "Phase III Double-blind, Placebo-controlled Study of AZD7442 for Pre-exposure Prophylaxis of COVID-19 in Adult."
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "None stated"
    }
  ],
  "next": "/api/comparisons/v1?page=86",
  "request_id": "i0fb6f8OZ9zPxM-E"
}